contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


bulletin-from-the-extraordinary-general-meeting-of-calliditas-therapeutics-ab-publ

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Calliditas Therapeutics

The following resolutions were passed at Calliditas Therapeutics AB (publ) ("Calliditas") extraordinary general meeting held today, on 30 September 2024, in Stockholm.Determination of the number...

<div class="abstract">The following resolutions were passed at Calliditas Therapeutics AB (publ) ("Calliditas") extraordinary general meeting held today, on 30 September 2024, in Stockholm.</div>Determination of the number of board membersThe extraordinary general meeting resolved, in accordance with Asahi Kasei Corporation's proposal, that the number of members of the board of directors to be elected by the general meeting shall be three (3) without alternate members of the board of directors.Election and removal of board members&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The extraordinary general meeting resolved, in accordance with Asahi Kasei Corporation's proposal, that Mark E. Hensley, Yoshikazu Aoki and Masaya Eto are elected as new members of the board of directors for the period until the end of the next annual general meeting, that Mark E. Hensley is elected as chairman of the board of directors for the period until the end of the next annual general meeting and that Elmar Schnee, Elisabeth Björk, Frederick Driscoll, Hilde Furberg, Diane Parks and Henrik Stenqvist are removed from their positions as members of the board of directors.Determination of fees to the board membersThe extraordinary general meeting resolved, in accordance with Asahi Kasei Corporation's proposal, that no fees shall be paid to the members of the board of directors.Resolution that the principles for appointing the nomination committee shall no longer apply after the delisting of Calliditas' shares from Nasdaq StockholmThe extraordinary general meeting resolved, in accordance with Asahi Kasei Corporation's proposal, that the principles and the instructions for the appointment of the members of the nomination committee, which was adopted by the extraordinary general meeting 2017, shall no longer apply when Calliditas' shares are delisted from Nasdaq Stockholm.Resolution that the guidelines on remuneration to group management and board members shall no longer apply after the delisting of Calliditas' shares from Nasdaq StockholmThe extraordinary general meeting resolved, in accordance with Asahi Kasei Corporation's proposal, that the guidelines on remuneration to group management and board members, which was adopted by the annual general meeting 2024, shall no longer apply when Calliditas' shares are delisted from Nasdaq Stockholm.For further information, please contact:Åsa Hillsten, Head of IR &amp; SustainabilityE-mail: asa.hillsten@calliditas.comTelephone: + 46 76 403 35 43The information was submitted for publication, through the agency of the contact person set out above, at 14:30 CEST on 30 September 2024.About CalliditasCalliditas Therapeutics is a biopharma company headquartered in Stockholm, Sweden, focused on identifying, developing, and commercializing novel treatments in orphan indications with significant unmet medical needs. Calliditas' common shares are listed on Nasdaq Stockholm (ticker: CALTX). Visit Calliditas.com for further information.

Bulletin from the extraordinary general meeting of Calliditas Therapeutics AB (publ)